Stem Cell Theranostics
TypePrivate
IndustryBiotechnology
Headquarters
Redwood City, California
,
United States

Stem Cell Theranostics is a privately held biotech company based out of Redwood City, California that provides drug companies with a method to more accurately predict cardiotoxicity and cardiovascular drug efficacy.[1]

History

Stem Cell Theranostics was one of the first med tech startup to come out of the StartX incubator program. The company uses technology developed at Stanford,[2][3] to create a "clinical trial in a dish" drug screening platform, which reduces the risk of drug development.[4] The company currently works with drug discovery and biotechnology companies to use patient-specific induced pluripotent stem cells for development of novel therapeutics.[5]

References

  1. ↑ Deanna Pogorelc. "Merck and J&J back StartX; "clinical-trial-in-a-dish" biotech wows at Demo Day". MedCity News. Retrieved 11 November 2014.
  2. ↑ Krista Conger. "Scientists show that lab-made heart cells can be ideal model for disease research, drug testing". News Center. Retrieved 11 November 2014.
  3. ↑ Krista Conger. "Researchers use stem cells to pinpoint cause of common type of sudden cardiac death". News Center. Retrieved 11 November 2014.
  4. ↑ "Stem Cell Theranostics' clinical trial in a dish". Silicon Valley Business Journal. 29 March 2013. Retrieved 11 November 2014.
  5. ↑ "The Experiment Begins: Y Combinator Admits First Biotech Startups". Xconomy. Retrieved 11 November 2014.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.